Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

Monoclonal antibodies (MAbs) have revolutionized the treatment of many chronic inflammatory diseases, including inflammatory bowel disease (IBD). IBD is a term that comprises two quite similar, yet distinctive, disorders—Crohn’s disease (CD) and ulcerative colitis (UC). Two blockbuster MAbs, inflixi...

Full description

Bibliographic Details
Main Authors: Zvonimir Petric, Joao Goncalves, Paulo Paixao
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
monoclonal antibodies
inflammatory bowel disease
anti-TNF-α agents
infliximab (IFX)
adalimumab (ADL)
immunogenicity
Online Access:https://www.mdpi.com/1999-4923/14/9/1766

Internet

https://www.mdpi.com/1999-4923/14/9/1766

Similar Items